Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

DDMX, ATRO, TTEC, NHPR, PWRM - Stock News! from CRWEfinance.com

crwefinancelogo2

signup3m

___

http://pennyomega.com/img/nhpr.jpg  National Health Partners, Inc. (OTC:NHPR)

How much health insurance will set you back depends on your age, the status of your health (how strong or sick you are), where in the country you live, your income, and your job status.

The obligation for affordable healthcare selections has never been in more need.

Mr. Daniels states “We are seeing continuous growth during the current 4th quarter which should provide strong momentum for the 1st quarter of 2011. Our future has never looked brighter and I am quite confident that we will be able to see accelerating growth in both revenues and earnings. With our continued focus on keeping our operating costs down while at the same time building our revenues at an accelerating rate, we are in a very good position to see very strong earnings growth going forward. I will be providing more information on new business ventures in the very near term that will change the entire complexion of the company and I look forward to continuing to build on the success that we have already started achieving in the 3rd quarter.”

National Health Partners, Inc., a national healthcare membership organization, creates, markets, and sells membership programs to underserved markets in the healthcare industry in the United States. NHPR's programs provide an alternative to individuals who seek to reduce their healthcare costs not covered by insurance, or who are unable to obtain healthcare insurance due to their medical history, age, or occupation. NHPR was founded in 1989 and is headquartered in Horsham, Pennsylvania.

To learn more about NHPR visit:  http://www.nationalhealthpartners.com

*****

Dynamex Inc. (Nasdaq:DDMX) announced that it has received (i) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) with respect to the proposed merger (the “Merger”) with TransForce Inc. (“TransForce”), (ii) a “no action letter” from the Canadian Competition Bureau (the “Bureau”) indicating that the commissioner of the Bureau does not at this time intend to make an application for an order under Section 92 of the Competition Act (Canada), R.S.C. 1985, c. C-34 and regulations thereto, as amended (the “Competition Act”), to challenge the Merger and (iii) a notice from the Canadian Minister of Transport, Infrastructure and Communities that the Merger does not raise public interest issues as it relates to national transportation in Canada under the Canada Transportation Act, 1996, c. 10 and regulations thereto, as amended (the “Transportation Act”).

Dynamex Inc. and its subsidiaries provide delivery and logistics services in the United States and Canada. It offers same-day, on-demand, and door-to-door delivery services utilizing its ground couriers. Dynamex was founded in 1992 and is based in Dallas, Texas.

*****

Power3 Medical Products, Inc. (OTC:PWRM)

World-wide, breast cancer comprises 10.4% of all melanoma incidence among women, which makes it the most widespread kind of non-skin cancer in women and the 5th most widespread reason behind cancer death. In 2004, breast cancer brought on 519,000 fatalities world-wide (7% of cancer deaths; essentially 1% of all deaths. Breast cancer is about one hundred times more frequent with women of all ages in comparison with men, even though males tend to have worse outcomes because of delays in diagnosis.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

How BC-SeraPro Works

BC-SeraPro is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will monitor the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer. The biomarkers in the panel have been selected for their ability to discriminate breast cancer patients from non-cancerous patients. Power3’s statistical model evaluates the quantitative information of the protein biomarkers and automatically assigns a probability score. The probability score indicates to the physician that the patient “has cancer” or is “cancer-free”. The score reflects how strongly the patient sample fits the biostatistical model and if the patient should be recommended for further follow-up by the clinician.

Blood serum collection is a routine procedure performed by a clinician. A small sample of blood is drawn from a vein. When a blood sample is collected and stored in a tube without anticoagulant, it forms a clot after 30-60 minutes. The liquid portion remaining is the blood serum. This serum sample is then frozen and transported to the Power3 Medical CLIA certified laboratory, utilizing pre-approved carriers/delivery service, where sample preparation and analysis begins.

To learn more about PWRM visit: http://www.Power3Medical.com

*****

Astronics Corp. (Nasdaq:ATRO) a leader in advanced, high performance lighting, electrical power and automated test systems for the global aerospace and defense industries, announced that Peter J. Gundermann, President & Chief Executive Officer, and David C. Burney, Chief Financial Officer, will present at the Cowen and Company 32nd Annual Aerospace/Defense Conference at the InterContinental The Barclay in New York City on Wednesday, February 9, 2011.

Astronics Corporation, through its subsidiaries, designs and manufactures products for the aerospace and defense industries. It offers lighting systems, electrical power generation systems, aircraft safety systems, and electrical power distribution systems for the aerospace industry.

*****

TeleTech Holdings Inc. (Nasdaq:TTEC) one of the world's largest global providers of comprehensive enterprise solutions, has been selected by a major financial services information company to provide customer care and retention support for its consumer division. Company was chosen for its high security standards and best-in-class human capital and performance management processes.

TeleTech Holdings, Inc. provides onshore, offshore, and work-from-home business process outsourcing services focusing on revenue generation, customer and enterprise management, and technology enabled solutions worldwide.

___

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.  Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).  Crown Equity Holdings Inc. (OTCPK:CRWE) has received 3,000,000 shares of (144) restricted common stock from the company and anticipates receiving 3,000,000 shares of free trading shares from a third party for six months of advertisement services for National Health Partners Inc. (OTC:NHPR).